Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Burning Rock Biotech's operating assets for the quarter that ended in Mar. 2026 was €42.90 Mil. Burning Rock Biotech's operating liabilities for the quarter that ended in Mar. 2026 was €27.67 Mil. Burning Rock Biotech's Total Assets for the quarter that ended in Dec. 2025 was €99.47 Mil. Therefore, Burning Rock Biotech's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.15.
Burning Rock Biotech Scaled Net Operating Assets Related Terms
Burning Rock Biotech Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech Scaled Net Operating Assets Chart
FRA:6BU0 vs XGN, IDXG, PRPO: Scaled Net Operating Assets Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Scaled Net Operating Assets vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.15 mean?
Burning Rock Biotech (FRA:6BU0) has a Scaled Net Operating Assets of 0.15 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Scaled Net Operating Assets too high?
Burning Rock Biotech's current Scaled Net Operating Assets is 0.15. Overall, Burning Rock Biotech has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Scaled Net Operating Assets compare to XGN and IDXG?
Burning Rock Biotech's Scaled Net Operating Assets of 0.15 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Diagnostics & Research company?
A good Scaled Net Operating Assets depends on the Medical Diagnostics & Research industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current Scaled Net Operating Assets is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.65, compared to a current price of €7.80 — trading 38.1% above its estimated fair value. The current Scaled Net Operating Assets is 0.15. Burning Rock Biotech's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Scaled Net Operating Assets is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €7.80 is trading 38.1% above its estimated GF Value™ of €5.65.
GuruFocus considers Burning Rock Biotech to be Modestly Undervalued.
Key valuation signals for FRA:6BU0:
Scaled Net Operating Assets: 0.15
GF Value™: €5.65 vs. price of €7.80 (38.1% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
61GF Score
Get the complete analysis for FRA:6BU0
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
